Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study

被引：0
|
作者：
Kensei Tobinai
Toshiki Uchida
Noriko Fukuhara
Tomoaki Nishikawa
机构：
[1] National Cancer Center Hospital,Department of Hematology
[2] Japanese Red Cross Nagoya Daini Hospital,undefined
[3] Tohoku University Hospital,undefined
[4] Janssen Pharmaceutical K.K.,undefined
来源：
International Journal of Hematology | 2019年 / 109卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：366 / 368
页数：2
相关论文
共 50 条
  • [41] Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies
    Dowlati, A
    Lazarus, HM
    Hartman, P
    Jacobberger, JW
    Whitacre, C
    Gerson, SL
    Ksenich, P
    Cooper, BW
    Frisa, PS
    Gottlieb, M
    Murgo, AJ
    Remick, SC
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 5929 - 5935
  • [42] A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Ogawa, Yoshiaki
    Ogura, Michinori
    Suzuki, Tatsuya
    Ando, Kiyoshi
    Uchida, Toshiki
    Shirasugi, Yukari
    Tobinai, Kensei
    Lee, Je Hwan
    Kase, Masazumi
    Katsura, Koichi
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (02) : 164 - 170
  • [43] A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma
    Lee, Hun J.
    Schmelz, Jacob L.
    Cramer, Fred
    Romaguera, Jorge E.
    Badillo, Maria
    Wang, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : E94 - E98
  • [44] A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas
    Rutherford, Sarah C.
    Allan, John N.
    Ruan, Jia
    Furman, Richard R.
    Richards, Kristy
    Rodriguez, Amelyn
    Gololobova, Kseniya
    Garcia, Arcania
    Cerchietti, Leandro
    Marullo, Rossella
    Chen, Zhengming
    Santamala, Jennifer
    Shore, Tsiporah B.
    Phillips, Adrienne A.
    Mayer, Sebastian
    Hsu, Jingmei
    Gergis, Usama
    Senese, Silvia
    Ali-Shaw, Trisha
    Rahim, Riyaad
    van Besien, Koen
    Leonard, John P.
    Martin, Peter
    BLOOD, 2020, 136
  • [45] Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final Analysis
    Maerevoet, Marie
    Casasnovas, Olivier
    Cartron, Guillaume
    Morschhauser, Franck
    Thieblemont, Catherine
    Bouabdallah, Kamal
    Feugier, Pierre
    Szablewski, Vanessa
    Becker, Stephanie
    Tilly, Herve
    CANCERS, 2024, 16 (15)
  • [46] A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies.
    Qiu, Lugui
    Qi, Junyuan
    Song, Yuqin
    Jiang, Bo
    Tu, Meifeng
    Ping, Lingyan
    Li, Zengjun
    Zhu, Jun
    Xu, Yuanyuan
    Bao, Hanying
    Xu, Zusheng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies
    Xu, Linlin
    Shadman, Mazyar
    Ponakala, Anusha
    Flinn, Ian W.
    Levy, Moshe Yair
    Porter, Ryan
    Burke, John M.
    Zafar, Syed F.
    Cultrera, Jennifer L.
    Misleh, Jamal
    Kingsley, Edwin C.
    Yimer, Habte
    Freeman, Benjamin
    Chaudhry, Arvind
    Tumula, Praveen K.
    Gandhi, Mitul
    Cohen, Aileen
    Chen, Dih-Yih
    Manda, Sudhir
    Sharman, Jeff P.
    Ramakrishnan, Vanitha
    BLOOD, 2022, 140 : 9269 - 9271
  • [48] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
    Advani, Ranjana H.
    Buggy, Joseph J.
    Sharman, Jeff P.
    Smith, Sonali M.
    Boyd, Thomas E.
    Grant, Barbara
    Kolibaba, Kathryn S.
    Furman, Richard R.
    Rodriguez, Sara
    Chang, Betty Y.
    Sukbuntherng, Juthamas
    Izumi, Raquel
    Hamdy, Ahmed
    Hedrick, Eric
    Fowler, Nathan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 88 - 94
  • [49] Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma
    Izutsu, Koji
    Kato, Koji
    Kiyoi, Hitoshi
    Yamamoto, Go
    Shimada, Kazuyuki
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (04) : 504 - 509
  • [50] Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma
    Koji Izutsu
    Koji Kato
    Hitoshi Kiyoi
    Go Yamamoto
    Kazuyuki Shimada
    Koichi Akashi
    International Journal of Hematology, 2020, 112 : 504 - 509
12345